Skip to content

Physostigmine

SENSORY ORGANS

Also known as: (-)-Physostigmine, cogmine, eserine, eserine hemisulfate, eserine hemisulfate salt, esromiotin, physostigmine salicylate

YEAR INTRODUCED approvedATC S01EB05ATC V03AB19

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Physostigmine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1875. DrugCentral lists 14 molecular targets, including ACHE, Ache and Ache. Recorded indications include Anticholinergic Toxicity and Open-angle glaucoma.

  • Molecular targets: ACHE, Ache, Ache and Bche (14 listed in DrugCentral).
  • Indications: Anticholinergic Toxicity and Open-angle glaucoma.
  • ATC code: S01EB05 (Parasympathomimetics).
  • Molecular formula: C15H21N3O2; molecular weight 275.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Anticholinergic Toxicity
  • Open-angle glaucoma

Off-label uses (3)

  • Angle-closure glaucoma
  • Hereditary Ataxias
  • Secondary glaucoma

Contraindications (15)

  • Anterior uveitis
  • Asthma
  • Bradycardia
  • Diabetes mellitus
  • Disorder of cardiovascular system
  • Epilepsy
  • Gangrene
  • Gastrointestinal obstruction
  • Iritis
  • Keratitis
  • Neuromuscular block, function
  • Parkinsonism
  • Pupillary Block Glaucoma
  • Retinal detachment
  • Urinary tract obstruction

Mechanism & targets

Molecular targets (14)

TargetGeneActionActivity
AcetylcholinesteraseACHEinhibitorIC50 9.37
AcetylcholinesteraseAcheunknownIC50 9.17
AcetylcholinesteraseAcheunknownIC50 9.17
Butyrylcholinesterase; Protein BcheBcheunknownIC50 8.12
AcetylcholinesteraseacheunknownIC50 7.96
ButyrylcholinesteraseBCHEunknownIC50 7.80
AcetylcholinesteraseACHEunknownIC50 7.70
AcetylcholinesteraseACHEunknownIC50 7.52
AcetylcholinesteraseacheunknownKi 7.47
CholinesteraseBCHEunknownKi 7.39
Cytochrome P450 2D6CYP2D6unknownIC50 6.70
CholinesteraseBcheunknownIC50 6.55
CholinesteraseBCHEunknownKi 5.30
Muscarinic acetylcholine receptor M1Chrm1unknownIC50 4.43

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1875-01-01YEAR INTRODUCED——

ATC classification

ATC codeTherapeutic hierarchy
S01EB05SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIGLAUCOMA PREPARATIONS AND MIOTICS › Parasympathomimetics
V03AB19VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Antidotes

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Anticholinergic syndrome121.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Physostigmine is on its molecule page.

Molecular formulaC15H21N3O2
Molecular weight275.35 g/mol
CAS number57-47-6
InChIKeyPIJVFDBKTWXHHD-HIFRSBDPSA-N
PubChem CID5983
CNC(=O)OC1=CC=C2N(C)[C@H]3N(C)CC[C@@]3(C)C2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Physostigmine used for?

DrugCentral lists the following indications for Physostigmine: Anticholinergic Toxicity and Open-angle glaucoma.

How does Physostigmine work?

Its molecular targets in DrugCentral include ACHE (inhibitor), Ache, Ache and Bche.

When was Physostigmine first approved?

Physostigmine was first approved by the YEAR INTRODUCED in 1875.

What is the chemical formula of Physostigmine?

Physostigmine has the molecular formula C15H21N3O2 and a molecular weight of 275.35 g/mol.

Browse: all drugs starting with P · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval1875-01-01
AgencyYEAR INTRODUCED
Targets14
Indications2
FormulaC15H21N3O2
DrugCentral ID2159
Interactive profile